Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework

被引:140
作者
Gold, Stefan M. [1 ,2 ]
Enck, Paul [3 ]
Hasselmann, Helge [1 ]
Friede, Tim [4 ]
Hegerl, Ulrich [5 ]
Mohr, David C. [6 ]
Otte, Christian [1 ]
机构
[1] Charite Univ Med Berlin, Campus Benjamin Franklin, Klin Psychiat & Psychotherapie, D-12203 Berlin, Germany
[2] Univ Klinikum Hamburg Eppendorf, Zentrum Mol Neurobiol, Inst Neuroimmunol & Multiple Sklerose INIMS, Hamburg, Germany
[3] Univ Klinikum Tubingen, Psychosomat Med & Psychotherapie, Tubingen, Germany
[4] Univ Med Gottingen, Inst Med Stat, Gottingen, Germany
[5] Univ Klinikum Leipzig, Stiftung Deutsch Depressionshilfe, Klin & Poliklin Psychiat & Psychotherapie, Leipzig, Germany
[6] Northwestern Univ, Feinberg Sch Med, Ctr Behav Intervent Technol, Chicago, IL 60611 USA
来源
LANCET PSYCHIATRY | 2017年 / 4卷 / 09期
关键词
MAJOR DEPRESSIVE DISORDER; ANXIETY DISORDERS; PLACEBO-RESPONSE; CLINICAL-TRIALS; WAITING-LIST; METAANALYSIS; PSYCHOTHERAPY; DESIGN; PHARMACOTHERAPY; ANTIDEPRESSANTS;
D O I
10.1016/S2215-0366(17)30153-0
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In psychiatry, comparative analyses of therapeutic options and the aggregation of data from clinical trials across different therapeutic approaches play an important role in clinical decision making, treatment guidelines, and health policy. This approach assumes that trials of pharmacological and behavioural therapies generally produce the same level of evidence when properly designed. However, trial design for behavioural interventions has some unique characteristics and control groups vary widely, which influence the effects observed in any given trial. In this Personal View, we review various control conditions typically used in psychiatry, outline their effect on the internal validity and expected effect size of a trial, and propose a decision framework for choosing a control condition depending on the risk to the patient population and the stage of development of the therapeutic intervention. We argue that the choice of control group and its justification need to be taken into consideration when comparing behavioural and pharmacological therapies.
引用
收藏
页码:725 / 732
页数:8
相关论文
共 33 条
  • [1] Do we underestimate the benefits of antidepressants?
    Adli, Mazda
    Hegerl, Ulrich
    [J]. LANCET, 2014, 383 (9926) : 1361 - 1362
  • [2] [Anonymous], 2016, LANCET PSYCHIAT, V3, P305
  • [3] [Anonymous], 2014, LANCET PSYCHIAT, V1, P403
  • [4] A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
    Chataway, Jeremy
    Nicholas, Richard
    Todd, Susan
    Miller, David H.
    Parsons, Nicholas
    Valdes-Marquez, Elsa
    Stallard, Nigel
    Friede, Tim
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (01) : 81 - 88
  • [5] Developing and evaluating complex interventions: the new Medical Research Council guidance
    Craig, Peter
    Dieppe, Paul
    Macintyre, Sally
    Michie, Susan
    Nazareth, Irwin
    Petticrew, Mark
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7676): : 979 - 983
  • [6] How to prove that your therapy is effective, even when it is not: a guideline
    Cuijpers, P.
    Cristea, I. A.
    [J]. EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2016, 25 (05) : 428 - 435
  • [7] The effects of blinding on the outcomes of psychotherapy and pharmacotherapy for adult depression: A meta-analysis
    Cuijpers, P.
    Karyotaki, E.
    Andersson, G.
    Li, J.
    Mergl, R.
    Hegerl, U.
    [J]. EUROPEAN PSYCHIATRY, 2015, 30 (06) : 685 - 693
  • [8] How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence
    Cuijpers, Pim
    Cristea, Ioana A.
    Karyotaki, Eirini
    Reijnders, Mirjam
    Huibers, Marcus J. H.
    [J]. WORLD PSYCHIATRY, 2016, 15 (03) : 245 - 258
  • [9] What are we doing to waiting list controls?
    Elliott, SA
    Brown, JSL
    [J]. BEHAVIOUR RESEARCH AND THERAPY, 2002, 40 (09) : 1047 - 1052
  • [10] Pragmatic Trials
    Ford, Ian
    Norrie, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (05) : 454 - 463